Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

Global Cell Free Protein Expression Market Trajectory & Analytics, 2022-2026: Rising Incidence of Cancer and the Demand for Biologics Spur the Adoption of Cell Free Protein Extraction - ResearchAndMarkets.com


The "Cell Free Protein Expression - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Cell Free Protein Expression Market to Reach $271.6 Million by 2026

Amid the COVID-19 crisis, the global market for Cell Free Protein Expression estimated at US$216.2 Million in the year 2022, is projected to reach a revised size of US$271.6 Million by 2026, growing at a CAGR of 5.7% over the analysis period.

Cell-free protein expression is ideal for experiments meant for characterizing protein-protein interactions and protein-nucleic acid interactions and for high-throughput and rapid expression of truncated or mutant proteins for the purpose of functional analysis. Another application for which the approach is considered ideal is mammalian protein expression with appropriate glycosylation and native PTMs (Post-translational Modifications).

The technique is also being increasingly used for stable isotopes containing proteins labeling, for the purpose of structural analysis and for the production of toxic polypeptides and functional virons. Researchers also use cell-free protein expression for analyzing components needed for protein stability, degradation and folding.

Protein-Protein Interaction, one of the segments analyzed in the report, is projected to grow at a 6.3% CAGR to reach US$147.9 Million by the end of the analysis period.

After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Protein Labeling segment is readjusted to a revised 4.8% CAGR for the next 7-year period. This segment currently accounts for a 24.1% share of the global Cell Free Protein Expression market.

The U.S. Market is Estimated at $110.3 Million in 2022, China is Forecast to Reach $25.7 Million by 2026

The Cell Free Protein Expression market in the U.S. is estimated at US$110.3 Million in the year 2022. The country currently accounts for a 51.51% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$25.7 Million in the year 2026 trailing a CAGR of 7.5% through the analysis period.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR while Rest of European market (as defined in the study) will reach US$27.7 Million by the close of the analysis period.

Several pharmaceutical companies have in the recent years started research in the protein expression domain. Several biotech companies have also recently started initiatives which necessitate extensive use of cell-free protein expression, which is anticipated to provide the required impetus to market growth at the global level. The biological sector is also trying to use swifter and more agile protein synthesis methods further enhancing market growth dynamics.

Furthermore, technology advancements of over the years resulted in use of new expression elements like specially designed promoters exhibiting more efficient genomic engineering and translation leading to improved translation efficiency. There are also now software controlled algorithms facilitating better yield.

Other growth factors include increasing outsourcing of R&D by biotechnological and pharmaceutical companies, patent cliff sales reduction resulting in increased pharmaceutical sector research intensity, declining research productivity, and growing expenditure on development of biosimilars.

Advanced applications and increasing demand for more efficient and simpler methods for protein production also promote market growth. Different applications for cell-free protein expression include enzyme engineering, protein-protein interaction, protein purification and protein labeling, with the application of protein-protein interactions accounting for the largest percentage in overall market revenues at the global level owing to strong R&D initiatives for generation of protein libraries.

Enzyme Engineering Segment to Reach $41.7 Million by 2026

In the global Enzyme Engineering segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment.

These regional markets accounting for a combined market size of US$27 Million will reach a projected size of US$39 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3 Million by the year 2026.

What's New for 2022?

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS (Total 34 Featured)

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. REGIONAL MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/phk5m7


These press releases may also interest you

at 07:05
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...

at 07:05
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...

at 07:04
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...

at 07:00
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 07:00
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...

at 07:00
César A. Lara, MD, introduces a groundbreaking solution for pain relief in the Tampa Bay area. Red Laser Therapy leverages the power of medical-grade red laser light to effectively address various types of pain, providing patients with a noninvasive...



News published on and distributed by: